HOUSTON, July 7, 2026
FibroBiologics, Inc. has announced the successful completion of the third manufacturing batch of its investigational CYWC628 drug product, a significant milestone supporting the company’s ongoing Phase 1/2 clinical trial evaluating the cell-based therapy for the treatment of diabetic foot ulcers (DFUs). The latest manufacturing campaign was completed under current Good Manufacturing Practice (cGMP) standards, reinforcing the company’s commitment to high-quality manufacturing and regulatory compliance as it advances regenerative medicine therapies toward clinical development. Following completion of this third production batch, FibroBiologics expects its existing drug supply to be sufficient to complete the entire Phase 1/2 clinical trial, eliminating the immediate need for additional manufacturing while generating meaningful operational cost savings. The announcement further strengthens the company’s position in the growing field of cell therapy and highlights continued progress in developing innovative fibroblast-based regenerative treatments for chronic diseases with significant unmet medical needs.
cGMP Manufacturing Supports Ongoing Clinical Development
The newly manufactured batch of CYWC628 is currently undergoing comprehensive quality control and safety testing before being released for clinical use, consistent with regulatory expectations for investigational biologic therapies. Manufacturing under cGMP standards ensures that every batch meets strict quality, consistency, and safety requirements necessary for use in human clinical studies. According to FibroBiologics, completion of only three manufacturing batches is expected to provide enough investigational drug product to support patient enrollment and treatment throughout the ongoing clinical trial.
Company leadership indicated that encouraging healing trends observed during the early stages of the study suggest there may also be surplus doses available for future research and development initiatives. By avoiding additional manufacturing campaigns, the company anticipates reducing short-term cash expenditures while improving operational efficiency, an important achievement for a clinical-stage biotechnology company advancing innovative regenerative therapies. FibroBiologics also expects to report statistically significant interim clinical data during the third quarter of 2026, providing investors, clinicians, and regulatory stakeholders with important insights into the therapy’s clinical performance.
CYWC628 Targets Diabetic Foot Ulcers Through Fibroblast Therapy
Advertisement
CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy designed to accelerate wound healing in patients suffering from refractory diabetic foot ulcers, a serious complication of diabetes that remains a major cause of hospitalization, infection, and lower-limb amputation worldwide. Preclinical research has demonstrated the therapy’s potential to significantly improve wound healing compared with existing treatment approaches, supporting its advancement into clinical evaluation. The ongoing prospective, multicenter, randomized Phase 1/2 clinical trial is assessing the safety, tolerability, and efficacy of CYWC628 by comparing standard wound care alone with standard care plus either a low-dose or high-dose formulation of the investigational therapy over a treatment period of up to twelve weeks.
FibroBiologics continues to build one of the industry’s broadest intellectual property portfolios focused on fibroblast science, with more than 270 issued and pending patents covering therapeutic applications across wound healing, multiple sclerosis, orthopedic disorders, psoriasis, disc degeneration, cancer, and longevity research. The successful completion of commercial-scale cGMP manufacturing for CYWC628 demonstrates FibroBiologics’ growing manufacturing capabilities while supporting continued clinical advancement of its regenerative medicine pipeline. As enrollment progresses and interim data approach, the company remains focused on generating robust clinical evidence that could position CYWC628 as a promising new treatment option for patients with difficult-to-heal diabetic foot ulcers and further strengthen the role of fibroblast-based regenerative medicine within the evolving biotechnology landscape.
Source: FibroBiologics press release
